Mitochondrial amplification selectively increases doxorubicin sensitivity in breast cancer cells with acquired antiestrogen resistance

Breast Cancer Research and Treatment

Volumn 129, Issue 3, 2011, Pages 785-797

  Skildum, Andrew ^a   Dornfeld, Kenneth ^a,b   Wallace, Kendall ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b Duluth Clinic   (United States)

Author keywords

Antiestrogen resistance; Breast cancer; Doxorubicin; Mitochondrial biogenesis; ROS; Sensitization; Troglitazone

Indexed keywords

ANTIESTROGEN; DOXORUBICIN; ESTROGEN RECEPTOR; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; SUPEROXIDE; TROGLITAZONE;

ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CANCER CELL CULTURE; CELL CYCLE PHASE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; DRUG SENSITIVITY; HUMAN; HUMAN CELL; MITOCHONDRIAL RESPIRATION; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSCRIPTION INITIATION; UPREGULATION;

ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CELLS, CULTURED; CHROMANS; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; EPITHELIAL CELLS; ESTROGEN RECEPTOR MODULATORS; FEMALE; HEAT-SHOCK PROTEINS; HUMANS; MITOCHONDRIA; PPAR GAMMA; REACTIVE OXYGEN SPECIES; RECEPTORS, ESTROGEN; THIAZOLIDINEDIONES; TRANSCRIPTION FACTORS;

EID: 80052604418     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-010-1268-2     Document Type: Article

References (61)

1. O Warburg 1956 On respiratory impairment in cancer cells Science 124 3215 269 270 13351639 1:STN:280:DyaG287gsVeksA%3D%3D
2. O Warburg 1956 On the origin of cancer cells Science 123 3191 309 314 13298683 10.1126/science.123.3191.309 1:STN:280:DyaG28%2FltV2ktQ%3D%3D
3. MG Vander Heiden LC Cantley CB Thompson 2009 Understanding the Warburg effect: the metabolic requirements of cell proliferation Science 324 5930 1029 1033 19460998 10.1126/science.1160809 1:CAS:528:DC%2BD1MXmtVKlsbg%3D
4. PP Hsu DM Sabatini 2008 Cancer cell metabolism: Warburg and beyond Cell 134 5 703 707 18775299 10.1016/j.cell.2008.08.021 1:CAS:528:DC%2BD1cXhtFCqs7jK
5. M Brandon P Baldi DC Wallace 2006 Mitochondrial mutations in cancer Oncogene 25 34 4647 4662 16892079 10.1038/sj.onc.1209607 1:CAS:528: DC%2BD28Xnsl2hsLY%3D (Pubitemid 44187615)
6. A Chatterjee E Mambo D Sidransky 2006 Mitochondrial DNA mutations in human cancer Oncogene 25 34 4663 4674 16892080 10.1038/sj.onc.1209604 1:CAS:528:DC%2BD28Xnsl2hsLs%3D (Pubitemid 44187616)
7. JS Penta, et al. 2001 Mitochondrial DNA in human malignancy Mutat Res 488 2 119 133 11344040 10.1016/S1383-5742(01)00053-9 1:CAS:528:DC%2BD3MXjtlent7o%3D (Pubitemid 32436427)
8. KK Singh 2006 Mitochondria damage checkpoint, aging, and cancer Ann N Y Acad Sci 1067 182 190 16803984 10.1196/annals.1354.022 1:CAS:528: DC%2BD28Xms1OksLo%3D (Pubitemid 43806323)
9. F Weinberg, et al. 2010 Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity Proc Natl Acad Sci USA 107 19 8788 8793 20421486 10.1073/pnas.1003428107 1:CAS:528:DC%2BC3cXmsFWmurs%3D
10. KJ Harrington, et al. 2000 Pegylated liposome-encapsulated doxorubicin and cisplatin enhance the effect of radiotherapy in a tumor xenograft model Clin Cancer Res 6 12 4939 4949 11156255 1:CAS:528:DC%2BD3MXotlertg%3D%3D (Pubitemid 32110440)
11. PW Pisters, et al. 2003 Phase I trial of preoperative concurrent doxorubicin and radiation therapy, surgical resection, and intraoperative electron-beam radiation therapy for patients with localized retroperitoneal sarcoma J Clin Oncol 21 16 3092 3097 12915599 10.1200/JCO.2003.01.143 1:CAS:528:DC%2BD2cXpsVWqtLk%3D (Pubitemid 46606290)
12. PW Pisters, et al. 2004 Phase I trial of preoperative doxorubicin-based concurrent chemoradiation and surgical resection for localized extremity and body wall soft tissue sarcomas J Clin Oncol 22 16 3375 3380 15310783 10.1200/JCO.2004.01.040 1:CAS:528:DC%2BD2cXpsVGrtrg%3D (Pubitemid 41103696)
13. YY Zaytseva, et al. 2008 Down-regulation of PPARgamma1 suppresses cell growth and induces apoptosis in MCF-7 breast cancer cells Mol Cancer 7 90 19061500 10.1186/1476-4598-7-90
14. J Patel RJ Anderson EB Rappaport 1999 Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve-week randomized, placebo-controlled study Diabetes Obes Metab 1 3 165 172 11220295 10.1046/j.1463-1326.1999.00020.x 1:CAS:528:DyaK1MXmsVaisb8%3D
15. SL Suter, et al. 1992 Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects Diabetes Care 15 2 193 203 1547676 10.2337/diacare.15. 2.193 1:STN:280:DyaK387ptFOksA%3D%3D
16. P Puigserver BM Spiegelman 2003 Peroxisome proliferator-activated receptor-gamma coactivator 1 alpha (PGC-1 alpha): transcriptional coactivator and metabolic regulator Endocr Rev 24 1 78 90 12588810 10.1210/er.2002-0012 1:CAS:528:DC%2BD3sXhslOgsbo%3D (Pubitemid 36223280)
17. SN Schreiber, et al. 2004 The estrogen-related receptor alpha (ERRalpha) functions in PPARgamma coactivator 1alpha (PGC-1alpha)-induced mitochondrial biogenesis Proc Natl Acad Sci USA 101 17 6472 6477 15087503 10.1073/pnas. 0308686101 1:CAS:528:DC%2BD2cXjvVyitLk%3D (Pubitemid 38585998)
18. P Puigserver, et al. 1998 A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis Cell 92 6 829 839 9529258 10.1016/S0092-8674(00)81410-5 1:CAS:528:DyaK1cXit1Klsb8%3D (Pubitemid 28155321)
19. CK Osborne R Schiff 2005 Estrogen-receptor biology: continuing progress and therapeutic implications J Clin Oncol 23 8 1616 1622 15755967 10.1200/JCO.2005.10.036 1:CAS:528:DC%2BD2MXjtVCqur0%3D (Pubitemid 46211414)
20. R Clarke, et al. 2003 Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling Oncogene 22 47 7316 7339 14576841 10.1038/sj.onc.1206937 1:CAS:528:DC%2BD3sXotlajurw%3D (Pubitemid 37492898)
21. HN Yu, et al. 2008 Troglitazone enhances tamoxifen-induced growth inhibitory activity of MCF-7 cells Biochem Biophys Res Commun 377 1 242 247 18835379 10.1016/j.bbrc.2008.09.111 1:CAS:528:DC%2BD1cXhtlaqsbzP
22. T Suzuki, et al. 2006 Peroxisome proliferator-activated receptor gamma in human breast carcinoma: a modulator of estrogenic actions Endocr Relat Cancer 13 1 233 250 16601291 10.1677/erc.1.01075 1:CAS:528:DC%2BD28XltlKrsr4%3D
23. DR Talbert, et al. 2008 Transactivation of ERalpha by Rosiglitazone induces proliferation in breast cancer cells Breast Cancer Res Treat 108 1 23 33 17453334 10.1007/s10549-007-9575-y (Pubitemid 351623235)
24. X Wang MW Kilgore 2002 Signal cross-talk between estrogen receptor alpha and beta and the peroxisome proliferator-activated receptor gamma1 in MDA-MB-231 and MCF-7 breast cancer cells Mol Cell Endocrinol 194 1-2 123 133 12242035 10.1016/S0303-7207(02)00154-5 1:CAS:528:DC%2BD38XntVaqu74%3D (Pubitemid 35291927)
25. Y Yin, et al. 2009 Inhibition of peroxisome proliferator-activated receptor gamma increases estrogen receptor-dependent tumor specification Cancer Res 69 2 687 694 19147585 10.1158/0008-5472.CAN-08-2446 1:CAS:528: DC%2BD1MXltFSgtQ%3D%3D
26. J Llopis, et al. 2000 Ligand-dependent interactions of coactivators steroid receptor coactivator-1 and peroxisome proliferator-activated receptor binding protein with nuclear hormone receptors can be imaged in live cells and are required for transcription Proc Natl Acad Sci USA 97 8 4363 4368 10760302 10.1073/pnas.97.8.4363 1:CAS:528:DC%2BD3cXislSns7k%3D (Pubitemid 30226138)
27. OS Gardner, et al. 2003 Dependence of peroxisome proliferator-activated receptor ligand-induced mitogen-activated protein kinase signaling on epidermal growth factor receptor transactivation J Biol Chem 278 47 46261 46269 12966092 10.1074/jbc.M307827200 1:CAS:528:DC%2BD3sXovFKltL4%3D (Pubitemid 37452196)
28. A Skildum E Faivre CA Lange 2005 Progesterone receptors induce cell cycle progression via activation of mitogen-activated protein kinases Mol Endocrinol 19 2 327 339 15486045 10.1210/me.2004-0306 1:CAS:528:DC%2BD2MXhsVCmt78%3D (Pubitemid 40223458)
29. MR Stampfer JC Bartley 1985 Induction of transformation and continuous cell lines from normal human mammary epithelial cells after exposure to benzo[a]pyrene Proc Natl Acad Sci USA 82 8 2394 2398 3857588 10.1073/pnas.82.8.2394 1:CAS:528:DyaL2MXitFKlt7k%3D (Pubitemid 15064494)
30. N Brunner, et al. 1997 MCF7/LCC9: an antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen Cancer Res 57 16 3486 3493 9270017 1:CAS:528:DyaK2sXls1Shu7o%3D (Pubitemid 27355496)
31. SC Brooks ER Locke HD Soule 1973 Estrogen receptor in a human cell line (MCF-7) from breast carcinoma J Biol Chem 248 17 6251 6253 4353636 1:CAS:528:DyaE3sXlsVejur8%3D
32. R Cailleau M Olive QV Cruciger 1978 Long-term human breast carcinoma cell lines of metastatic origin: preliminary characterization In Vitro 14 11 911 915 730202 10.1007/BF02616120 1:STN:280:DyaE1M%2FoslCqtQ%3D%3D (Pubitemid 9089089)
33. CK Osborne A Wakeling RI Nicholson 2004 Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action Br J Cancer 90 1 S2 S6 15094757 10.1038/sj.bjc.6601629 1:CAS:528:DC%2BD2cXjtFaktbY%3D (Pubitemid 38482618)
34. I Pagel-Langenickel, et al. 2008 PGC-1alpha integrates insulin signaling, mitochondrial regulation, and bioenergetic function in skeletal muscle J Biol Chem 283 33 22464 22472 18579525 10.1074/jbc.M800842200 1:CAS:528: DC%2BD1cXpsVKms7g%3D
35. PW Young, et al. 1998 Identification of high-affinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferator-activated receptor gamma J Pharmacol Exp Ther 284 2 751 759 9454824 1:CAS:528:DyaK1cXhtFWktLs%3D (Pubitemid 28086668)
36. X Li, et al. 2009 Troglitazone inhibits cell proliferation by attenuation of epidermal growth factor receptor signaling independent of peroxisome proliferator-activated receptor gamma Cell Res 19 6 720 732 19417774 10.1038/cr.2009.53 1:CAS:528:DC%2BD1MXms1OmtLk%3D
37. F Turturro, et al. 2004 Troglitazone acts on cellular pH and DNA synthesis through a peroxisome proliferator-activated receptor gamma-independent mechanism in breast cancer-derived cell lines Clin Cancer Res 10 20 7022 7030 15501982 10.1158/1078-0432.CCR-04-0879 1:CAS:528:DC%2BD2cXpslGlurk%3D (Pubitemid 39383054)
38. CC Yang, et al. 2007 Peroxisome proliferator-activated receptor gamma-independent suppression of androgen receptor expression by troglitazone mechanism and pharmacologic exploitation Cancer Res 67 7 3229 3238 17409431 10.1158/0008-5472.CAN-06-2759 1:CAS:528:DC%2BD2sXksVGksrs%3D (Pubitemid 46724861)
39. LM Leesnitzer, et al. 2002 Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662 Biochemistry 41 21 6640 6650 12022867 10.1021/bi0159581 1:CAS:528:DC%2BD38XjtF2htLo%3D (Pubitemid 34547354)
40. JM Berthiaume KB Wallace 2007 Adriamycin-induced oxidative mitochondrial cardiotoxicity Cell Biol Toxicol 23 1 15 25 17009097 10.1007/s10565-006-0140-y 1:CAS:528:DC%2BD28Xht12gs7fM (Pubitemid 44950185)
41. RJ Tallarida 2006 An overview of drug combination analysis with isobolograms J Pharmacol Exp Ther 319 1 1 7 16670349 10.1124/jpet.106.104117 1:CAS:528:DC%2BD28XhtVCksL%2FO (Pubitemid 44455105)
42. MG Vander Heiden, et al. 2010 Evidence for an alternative glycolytic pathway in rapidly proliferating cells Science 329 5998 1492 1499 20847263 10.1126/science.1188015 1:CAS:528:DC%2BC3cXhtFGjtLrK
43. HJ Burstein, et al. 2003 Use of the peroxisome proliferator-activated receptor (PPAR) gamma ligand troglitazone as treatment for refractory breast cancer: a phase II study Breast Cancer Res Treat 79 3 391 397 12846423 10.1023/A:1024038127156 1:CAS:528:DC%2BD3sXktlagsrs%3D (Pubitemid 36750946)
44. GF Davies BH Juurlink TA Harkness 2009 Troglitazone reverses the multiple drug resistance phenotype in cancer cells Drug Des Dev Ther 3 79 88 1:CAS:528:DC%2BD1MXoslSmsL8%3D
45. S Wei SK Kulp CS Chen 2010 Energy restriction as an antitumor target of thiazolidinediones J Biol Chem 285 13 9780 9791 20093366 10.1074/jbc.M109.065466 1:CAS:528:DC%2BC3cXjsFehtLg%3D
46. J Yan, et al. 2010 Autophagy augmented by troglitazone is independent of EGFR transactivation and correlated with AMP-activated protein kinase signaling Autophagy 6 1 67 73 19923924 10.4161/auto.6.1.10437 1:CAS:528: DC%2BC3cXlslGjsrw%3D
47. F Yin, et al. 2001 Troglitazone inhibits growth of MCF-7 breast carcinoma cells by targeting G1 cell cycle regulators Biochem Biophys Res Commun 286 5 916 922 11527386 10.1006/bbrc.2001.5491 1:CAS:528:DC%2BD3MXmtlejtL4%3D (Pubitemid 32924859)
48. Wang Y, Fang F, Wong CW Troglitazone is an estrogen-related receptor alpha and gamma inverse agonist. Biochem Pharmacol 80(1):80-85
49. KG Madsen, et al. 2008 Electrochemical oxidation of troglitazone: identification and characterization of the major reactive metabolite in liver microsomes Chem Res Toxicol 21 10 2035 2041 18788755 10.1021/tx8002214 1:CAS:528:DC%2BD1cXhtFWmt7vO
50. CM Loi, et al. 1999 Clinical pharmacokinetics of troglitazone Clin Pharmacokinet 37 2 91 104 10496299 10.2165/00003088-199937020-00001 1:CAS:528:DyaK1MXmsVGjtb4%3D (Pubitemid 29431478)
51. CM Loi, et al. 1997 Lack of effect of type II diabetes on the pharmacokinetics of troglitazone in a multiple-dose study J Clin Pharmacol 37 12 1114 1120 9506006 1:CAS:528:DyaK1cXktlyhtQ%3D%3D
52. YM Lee, et al. 2008 Mechanisms of 2-methoxyestradiol-induced apoptosis and G2/M cell-cycle arrest of nasopharyngeal carcinoma cells Cancer Lett 268 2 295 307 18492602 10.1016/j.canlet.2008.04.010 1:CAS:528:DC%2BD1cXps1GktrY%3D
53. T Russo, et al. 1995 A p53-independent pathway for activation of WAF1/CIP1 expression following oxidative stress J Biol Chem 270 49 29386 29391 7493974 10.1074/jbc.270.49.29386 1:CAS:528:DyaK2MXpvVOgsL4%3D
54. Hsu CW et al (2010) Mitochondrial DNA content as a potential marker to predict response to anthracycline in breast cancer patients. Breast J 16(3):264-270
55. K Fujisawa, et al. 2009 TZDs reduce mitochondrial ROS production and enhance mitochondrial biogenesis Biochem Biophys Res Commun 379 1 43 48 19084501 10.1016/j.bbrc.2008.11.141 1:CAS:528:DC%2BD1MXosVShtA%3D%3D
56. D Kukidome, et al. 2006 Activation of AMP-activated protein kinase reduces hyperglycemia-induced mitochondrial reactive oxygen species production and promotes mitochondrial biogenesis in human umbilical vein endothelial cells Diabetes 55 1 120 127 16380484 10.2337/diabetes.55.01.06.db05-0943 1:CAS:528:DC%2BD28XlvVSltg%3D%3D (Pubitemid 43343306)
57. M Fukano, et al. 2000 Subacute hepatic failure associated with a new antidiabetic agent, troglitazone: a case report with autopsy examination Hum Pathol 31 2 250 253 10685643 10.1016/S0046-8177(00)80229-4 1:STN:280: DC%2BD3c7kvVSkuw%3D%3D (Pubitemid 30090658)
58. PB Watkins RW Whitcomb 1998 Hepatic dysfunction associated with troglitazone N Engl J Med 338 13 916 917 9518284 10.1056/NEJM199803263381314 1:STN:280:DyaK1c7mslyhsA%3D%3D (Pubitemid 28135974)
59. MM Ong C Latchoumycandane UA Boelsterli 2007 Troglitazone-induced hepatic necrosis in an animal model of silent genetic mitochondrial abnormalities Toxicol Sci 97 1 205 213 17150972 10.1093/toxsci/kfl180 1:CAS:528: DC%2BD2sXlvVKjtLo%3D (Pubitemid 47072169)
60. Henney JE (2000) Withdrawal of Troglitazone and Cisapride. JAMA 283
61. LL Lipscombe, et al. 2007 Thiazolidinediones and cardiovascular outcomes in older patients with diabetes JAMA 298 22 2634 2643 18073359 10.1001/jama.298.22.2634 1:CAS:528:DC%2BD2sXhsVeqs77M (Pubitemid 350254955)